The long-term management of congenital generalized lipodystrophy (Berardinelli-Seip syndrome): the clinical manifestations of Japanese siblings for approximately 20 years
暂无分享,去创建一个
[1] K. Ozono,et al. Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report , 2019, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.
[2] P. Gorden,et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy , 2018, Endocrine.
[3] T. Urakami. New insights into the pharmacological treatment of pediatric patients with type 2 diabetes , 2018, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.
[4] M. Araujo,et al. Clinical outcome in a series of pediatric patients with congenital generalized lipodystrophies treated with dietary therapy , 2017, Journal of pediatric endocrinology & metabolism : JPEM.
[5] D. Cook,et al. Sleep Duration and Risk of Type 2 Diabetes , 2017, Pediatrics.
[6] J. Chaput,et al. Inadequate sleep as a contributor to type 2 diabetes in children and adolescents , 2017, Nutrition & diabetes.
[7] D. Kleiner,et al. Effects of Metreleptin in Pediatric Patients With Lipodystrophy , 2017, The Journal of clinical endocrinology and metabolism.
[8] D. Dunger,et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline , 2016, The Journal of clinical endocrinology and metabolism.
[9] P. Gorden,et al. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy , 2016, Expert review of clinical pharmacology.
[10] I. Pigeot,et al. Reference values for leptin and adiponectin in children below the age of 10 based on the IDEFICS cohort , 2014, International Journal of Obesity.
[11] C. Perry,et al. Metreleptin: First Global Approval , 2013, Drugs.
[12] M. Marcovecchio,et al. The Effects of Acute and Chronic Stress on Diabetes Control , 2012, Science Signaling.
[13] G. Sebag,et al. Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. , 2010, European journal of endocrinology.
[14] G. Sebag,et al. Metabolic Correction Induced by Leptin Replacement Treatment in Young Children With Berardinelli-Seip Congenital Lipoatrophy , 2007, Pediatrics.
[15] T. Kusakabe,et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. , 2007, The Journal of clinical endocrinology and metabolism.
[16] K. Nakao,et al. Long-term leptin-replacement therapy for lipoatrophic diabetes. , 2004, The New England journal of medicine.
[17] T. Kusakabe,et al. Gene and phenotype analysis of congenital generalized lipodystrophy in Japanese: a novel homozygous nonsense mutation in seipin gene. , 2004, The Journal of clinical endocrinology and metabolism.
[18] Y. Matsuzawa,et al. Serum adiponectin and leptin levels in patients with lipodystrophies. , 2004, The Journal of clinical endocrinology and metabolism.
[19] H. Mugishima,et al. Pharmacologic treatment strategies in children with type 2 diabetes mellitus. , 2013, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.